Trade Cytokinetics Inc - CYTK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.17 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 49.81 |
| Open | 49.71 |
| 1-Year Change | 54.04% |
| Day's Range | 47.58 - 50.1 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 47.58 | -2.37 | -4.74% | 49.95 | 50.26 | 47.54 |
| Nov 20, 2024 | 49.81 | -0.68 | -1.35% | 50.49 | 50.78 | 49.54 |
| Nov 19, 2024 | 51.02 | 0.02 | 0.04% | 51.00 | 51.55 | 49.60 |
| Nov 18, 2024 | 51.88 | 1.71 | 3.41% | 50.17 | 51.95 | 49.45 |
| Nov 15, 2024 | 50.19 | -4.61 | -8.41% | 54.80 | 54.86 | 49.74 |
| Nov 14, 2024 | 54.67 | -1.19 | -2.13% | 55.86 | 56.19 | 54.41 |
| Nov 13, 2024 | 55.91 | -0.64 | -1.13% | 56.55 | 57.61 | 55.90 |
| Nov 12, 2024 | 56.14 | -2.14 | -3.67% | 58.28 | 58.80 | 56.02 |
| Nov 11, 2024 | 58.58 | 0.55 | 0.95% | 58.03 | 59.30 | 57.79 |
| Nov 8, 2024 | 57.92 | 2.09 | 3.74% | 55.83 | 58.64 | 55.83 |
| Nov 7, 2024 | 55.73 | 1.23 | 2.26% | 54.50 | 57.38 | 54.50 |
| Nov 6, 2024 | 55.54 | 1.66 | 3.08% | 53.88 | 55.60 | 52.96 |
| Nov 5, 2024 | 52.47 | 1.45 | 2.84% | 51.02 | 52.92 | 50.74 |
| Nov 4, 2024 | 51.43 | 0.73 | 1.44% | 50.70 | 51.99 | 50.70 |
| Nov 1, 2024 | 51.77 | 0.65 | 1.27% | 51.12 | 52.26 | 50.96 |
| Oct 31, 2024 | 50.95 | 0.00 | 0.00% | 50.95 | 51.13 | 50.46 |
| Oct 30, 2024 | 51.27 | 0.39 | 0.77% | 50.88 | 52.01 | 50.88 |
| Oct 29, 2024 | 51.44 | -0.02 | -0.04% | 51.46 | 52.14 | 51.10 |
| Oct 28, 2024 | 52.21 | 0.54 | 1.05% | 51.67 | 53.20 | 51.45 |
| Oct 25, 2024 | 51.24 | -1.28 | -2.44% | 52.52 | 53.17 | 51.18 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cytokinetics Inc Company profile
About Cytokinetics, Inc.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cytokinetics, Inc. revenues increased 26% to $70.4M. Net loss increased 69% to $215.3M. Revenues reflect License revenues increase of 50% to $54.9M, Milestone revenues increase of 79% to $5M. Higher net loss reflects Research and development increase of 66% to $149.5M (expense), Other General and administrative increase of 91% to $80.4M (expense).
Equity composition
Common Stock $.001 Par, 02/11, 170M auth., 66,910,100 o/s. Insiders and Straegic holds 9.82%. 4/29/04, 5,800,000 shares @ $13 per share by Goldman, Sachs & Co. 25/13, 1-for-6 Reverse Stock split.
| Industry: | Bio Therapeutic Drugs |
350 Oyster Point Boulevard
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com